Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
BMY

BMY - Bristol-Myers Squibb Co Stock Price, Fair Value and News

51.32USD+0.41 (+0.81%)Market Closed
Watchlist

Market Summary

USD51.32+0.41
Market Closed
0.81%

BMY Stock Price

View Fullscreen

BMY RSI Chart

BMY Valuation

Market Cap

103.8B

Price/Earnings (Trailing)

17.7

Price/Sales (Trailing)

2.31

EV/EBITDA

6.83

Price/Free Cashflow

8.2

BMY Price/Sales (Trailing)

BMY Profitability

EBT Margin

18.75%

Return on Equity

19.92%

Return on Assets

6.16%

Free Cashflow Yield

12.19%

BMY Fundamentals

BMY Revenue

Revenue (TTM)

45.0B

Rev. Growth (Yr)

0.62%

Rev. Growth (Qtr)

4.66%

BMY Earnings

Earnings (TTM)

5.9B

Earnings Growth (Yr)

16.64%

Earnings Growth (Qtr)

103.58%

Breaking Down BMY Revenue

Last 7 days

0.1%

Last 30 days

-0.9%

Last 90 days

-1.9%

Trailing 12 Months

-30.9%

How does BMY drawdown profile look like?

BMY Financial Health

Current Ratio

1.43

Debt/Equity

1.09

Debt/Cashflow

0.43

BMY Investor Care

Dividend Yield

3.69%

Dividend/Share (TTM)

1.84

Buy Backs (1Y)

3.65%

Diluted EPS (TTM)

3.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202345.8B45.2B44.9B45.0B
202247.0B47.1B46.7B46.2B
202142.8B44.4B45.5B46.4B
202031.0B34.9B39.4B42.5B
201923.3B23.9B24.2B26.1B
201821.0B21.6B22.0B22.6B
201720.0B20.2B20.6B20.8B
201616.9B17.6B18.5B19.4B
201516.1B16.4B16.5B16.6B
201416.4B16.2B16.1B15.9B
201316.2B15.8B16.1B16.4B
201221.5B20.5B18.9B17.6B
201119.7B20.4B20.9B21.2B
201019.3B19.4B19.4B19.5B
200917.1B16.6B16.1B18.8B
200816.1B16.7B17.2B17.7B
200700015.6B

Tracking the Latest Insider Buys and Sells of Bristol-Myers Squibb Co

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
meyers gregory scott
sold (taxes)
-36,697
48.67
-754
evp, chief digital & tech off.
Feb 01, 2024
meyers gregory scott
acquired
-
-
2,543
evp, chief digital & tech off.
Dec 05, 2023
boerner christopher s.
bought
99,560
49.78
2,000
chief executive officer
Dec 02, 2023
boerner christopher s.
acquired
-
-
2,638
chief executive officer
Dec 02, 2023
plenge robert m
acquired
-
-
616
evp, chief research officer
Dec 02, 2023
plenge robert m
sold (taxes)
-13,727
50.1
-274
evp, chief research officer
Dec 02, 2023
boerner christopher s.
sold (taxes)
-67,635
50.1
-1,350
chief executive officer
Dec 02, 2023
elkins david v
acquired
-
-
8,792
evp, chief financial officer
Dec 02, 2023
elkins david v
sold (taxes)
-186,873
50.1
-3,730
evp, chief financial officer
Nov 28, 2023
boerner christopher s.
bought
150,049
48.86
3,071
chief executive officer

1–10 of 50

Which funds bought or sold BMY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
V-Square Quantitative Management LLC
added
99.99
758,560
1,746,280
0.31%
Feb 21, 2024
WNY Asset Management, LLC
reduced
-0.99
-58,627
411,681
0.07%
Feb 21, 2024
SMITH SHELLNUT WILSON LLC /ADV
unchanged
-
-36,375
277,331
0.16%
Feb 21, 2024
Raleigh Capital Management Inc.
added
186
123,023
203,494
0.10%
Feb 21, 2024
Garde Capital, Inc.
added
23.87
12,000
130,000
0.01%
Feb 20, 2024
Pacific Center for Financial Services
unchanged
-
-18,555
141,462
0.04%
Feb 20, 2024
Able Wealth Management LLC
new
-
90,126
90,126
0.08%
Feb 20, 2024
VOISARD ASSET MANAGEMENT GROUP, INC.
new
-
73,403
73,403
0.04%
Feb 20, 2024
READYSTATE ASSET MANAGEMENT LP
new
-
7,132
7,132
-%
Feb 20, 2024
GLOBALT Investments LLC / GA
new
-
3,569,550
3,569,550
0.15%

1–10 of 47

Are Funds Buying or Selling BMY?

Are funds buying BMY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMY
No. of Funds

Unveiling Bristol-Myers Squibb Co's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.74%
198,155,594
SC 13G/A
Jan 25, 2024
blackrock inc.
8.3%
168,098,227
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
202,927,620
SC 13G/A
Feb 07, 2023
blackrock inc.
8.1%
172,720,377
SC 13G/A
Feb 09, 2022
vanguard group inc
9.00%
199,834,483
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
169,226,706
SC 13G/A
Feb 10, 2021
vanguard group inc
8.82%
199,340,458
SC 13G/A
Jan 29, 2021
blackrock inc.
7.6%
172,464,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.32%
194,860,154
SC 13G/A
Feb 05, 2020
blackrock inc.
7.3%
171,343,446
SC 13G/A

Recent SEC filings of Bristol-Myers Squibb Co

View All Filings
Date Filed Form Type Document
Feb 22, 2024
8-K
Current Report
Feb 16, 2024
424B5
Prospectus Filed
Feb 16, 2024
SC TO-T/A
SC TO-T/A
Feb 15, 2024
8-K
Current Report
Feb 15, 2024
FWP
Prospectus Filed
Feb 14, 2024
8-K
Current Report
Feb 13, 2024
10-K
Annual Report
Feb 13, 2024
424B2
Prospectus Filed
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC TO-T/A
SC TO-T/A

What is the Fair Value of BMY?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Bristol-Myers Squibb Co)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
20.7M
84.1M
58.23% -28.98%
-0.97
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Bristol-Myers Squibb Co News

Latest updates
MarketWatch13 hours ago
Investor's Business Daily02 Feb 202408:00 am
The Motley Fool25 Jan 202408:00 am

Bristol-Myers Squibb Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.7%11,47710,96611,22611,33711,40611,21811,88711,64811,98511,62411,70311,07311,06810,54010,12910,7817,9456,0076,2735,9205,973
Gross Profit-------------8,1588,0387,4307,1195,4534,2174,3014,096-
Costs and Expenses11.0%9,8038,8299,3678,5679,5479,0099,9299,96110,1279,46710,1508,54321,5198,2838,50211,0858,0744,6584,4973,9414,468
  S&GA Expenses3.5%2,0732,0031,9341,7622,2661,9301,7871,8312,3541,7881,8821,6662,7211,7061,6281,6061,7341,0551,0761,0061,336
  R&D Expenses10.5%2,4782,2422,2582,3212,5102,4182,3212,2602,5182,9802,4782,2192,6552,4992,5222,3722,0971,3781,3251,3481,367
EBITDA Margin-1.5%0.40*0.41*0.41*0.41*0.39*0.39*0.38*0.38*0.40*0.14*0.15*0.15*0.08*0.31*0.26*0.22*-----
Income Taxes-143.3%-88.00203-218503-166601529404-514605492501-4243791,707462931-17.00337264347
Earnings Before Taxes-21.7%1,6742,1371,8592,7701,8592,2091,9581,6871,8582,1571,5532,530-10,4512,2571,627-304-1291,3491,7761,9791,505
EBT Margin-2.3%0.19*0.19*0.19*0.19*0.17*0.17*0.16*0.15*0.17*-0.09*-0.09*-0.09*-0.16*0.09*0.07*0.09*-----
Net Income103.6%3,9251,9284.005.003,3651,6068.005.003,9171,546-6.00-8.00-10,0271,872-5.00-9.00-1,0561,3531,4321,7101,160
Net Income Margin10.4%0.13*0.12*0.11*0.11*0.11*0.12*0.12*0.12*0.12*-0.19*-0.18*-0.19*-0.19*0.02*0.01*0.06*-----
Free Cashflow-11.0%3,9224,4091,6282,6922,9603,4401,9893,5593,7374,9962,8503,6513,0722,1144,3623,751-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.3%95,15991,26393,48994,28196,82098,196100,357103,034109,314110,893110,797112,435118,481125,536128,076129,285129,94457,43355,16334,83434,986
  Current Assets15.0%31,77027,63228,07427,08627,27326,79630,18630,12133,26231,44329,16127,11130,19234,27734,34331,85329,35440,19137,71617,09317,716
    Cash Equivalents53.3%11,5197,5148,3728,9959,1237,95710,96012,57914,31613,87911,39711,32114,97319,86020,36216,24612,82030,48928,4047,3356,911
  Inventory9.3%2,6622,4362,3642,6052,3392,0742,1422,1042,0952,1632,1371,9532,0741,9492,3842,8364,2931,1921,3081,2831,195
  Net PPE2.5%6,6466,4816,3556,2796,2556,0355,9706,0476,0495,8685,7955,7635,8865,7405,7776,1126,2524,8304,8494,9855,027
  Goodwill0.1%21,16921,14721,16321,16221,14921,11220,44620,50020,50220,51920,52920,52420,54720,51720,57822,45222,4886,5136,5336,5366,538
Liabilities5.6%65,67462,20161,45962,39565,70265,46267,69671,38973,30873,60973,92374,76280,59975,30678,91679,30878,24639,67939,01219,51720,859
  Current Liabilities-5.1%22,26223,46220,15019,08521,89018,93020,91522,82121,86821,46018,99117,33019,08020,46423,42119,23218,30410,4899,7118,84110,654
  Long Term Debt-100.0%-32,13734,65635,07835,05636,96637,10737,45039,60539,67742,50344,50548,33644,61446,10646,10546,15024,39024,4335,6355,646
    LT Debt, Non Current14.1%36,65332,13734,65635,07835,05636,96637,10737,45039,60539,67742,50344,50548,33641,36441,85342,84443,38724,39024,4335,6355,646
Shareholder's Equity1.5%29,43028,99845,29945,14031,06144,95644,37543,75644,36144,29244,06443,85244,32550,23049,16049,97743,70917,75416,15115,3172,081
  Retained Earnings1.9%28,76628,21827,44926,56825,50324,67524,21723,94823,82022,62522,16822,20421,28132,41431,56532,67134,47436,55535,87035,10934,065
  Additional Paid-In Capital1.9%45,68444,84945,29945,14045,16544,95644,37543,75644,36144,29244,06443,85244,32544,43544,44443,25443,7092,2062,1502,1032,081
Shares Outstanding------2,1262,1352,129-2,2202,2222,233-2,2602,2542,263-1,6291,6361,636-
Minority Interest-14.1%55.0064.0057.0062.0057.0063.0061.0065.0060.0071.0066.0068.0060.0072.0066.0066.0010010610299.0096.00
Float-------164,301---148,383---132,443---74,102--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-10.5%4,2524,7511,8872,9703,3063,6872,2613,8124,0575,2663,0603,8243,3552,2674,4933,9372,1812,5562,0831,3903,555
  Share Based Compensation-3.8%12713213712211911511610713314215715117118521321028456.0048.0053.0053.00
Cashflow From Investing-228.3%-1,346-410-329-2101,213-2,081-28995.00401-976180-143-11,812-213556610-12,1794917151,060-1,462
Cashflow From Financing118.7%967-5,160-2,173-3,050-3,246-4,543-3,520-5,653-3,967-1,780-3,182-7,2953,483-2,587-993-1,054-7,677-94118,268-2,029-578
  Dividend Payments-2.6%1,1601,1911,1971,1961,1451,1541,1501,1851,0991,0901,0991,1081,0211,0161,0211,017668671671669653
  Buy Backs-100.0%-4,0009052502,416701-5,0002,7515251,2361,7751,465--81.007,000300---

BMY Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Total Revenues$ 45,006$ 46,159$ 46,385
Cost of products sold[1]10,69310,1379,940
Marketing, selling and administrative7,7727,8147,690
Research and development9,2999,50910,195
Acquired IPRD9138151,159
Amortization of acquired intangible assets9,0479,59510,023
Other (income)/expense, net(1,158)576(720)
Total Expenses36,56638,44638,287
Earnings Before Income Taxes8,4407,7138,098
Provision for Income Taxes4001,3681,084
Net Earnings8,0406,3457,014
Noncontrolling Interest151820
Net Earnings Attributable to BMS$ 8,025$ 6,327$ 6,994
Earnings per Common Share   
Basic (in dollars per share)$ 3.88$ 2.97$ 3.15
Diluted (in dollars per share)$ 3.86$ 2.95$ 3.12
Net product sales   
Total Revenues$ 43,778$ 44,671$ 45,055
Alliance and other revenues   
Total Revenues$ 1,228$ 1,488$ 1,330
[1]Excludes amortization of acquired intangible assets.

BMY Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 11,464$ 9,123
Marketable debt securities816130
Receivables10,9219,886
Inventories2,6622,339
Other current assets5,9075,795
Total Current assets31,77027,273
Property, plant and equipment6,6466,255
Goodwill21,16921,149
Other intangible assets27,07235,859
Deferred income taxes2,7681,344
Marketable debt securities3640
Other non-current assets5,3704,940
Total Assets95,15996,820
Current Liabilities:  
Short-term debt obligations3,1194,264
Accounts payable3,2593,040
Other current liabilities15,88414,586
Total Current liabilities22,26221,890
Deferred income taxes3382,166
Long-term debt36,65335,056
Other non-current liabilities6,4216,590
Total Liabilities65,67465,702
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders’ Equity:  
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,953 in 2023 and 2,991 in 2022, liquidation value of $50 per share00
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2023 and 2022292292
Capital in excess of par value of stock45,68445,165
Accumulated other comprehensive loss(1,546)(1,281)
Retained earnings28,76625,503
Less cost of treasury stock — 902 million common shares in 2023 and 825 million common shares in 2022(43,766)(38,618)
Total BMS Shareholders’ Equity29,43031,061
Noncontrolling interest5557
Total Equity29,48531,118
Total Liabilities and Equity$ 95,159$ 96,820
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
 CEO
 WEBSITEwww.bms.com
 EMPLOYEES34300

Bristol-Myers Squibb Co Frequently Asked Questions


What is the ticker symbol for Bristol-Myers Squibb Co? What does BMY stand for in stocks?

BMY is the stock ticker symbol of Bristol-Myers Squibb Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bristol-Myers Squibb Co (BMY)?

As of Thu Feb 22 2024, market cap of Bristol-Myers Squibb Co is 103.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers. The fair value of Bristol-Myers Squibb Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bristol-Myers Squibb Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bristol-Myers Squibb Co a good stock to buy?

The fair value guage provides a quick view whether BMY is over valued or under valued. Whether Bristol-Myers Squibb Co is cheap or expensive depends on the assumptions which impact Bristol-Myers Squibb Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMY.

What is Bristol-Myers Squibb Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, BMY's PE ratio (Price to Earnings) is 17.7 and Price to Sales (PS) ratio is 2.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bristol-Myers Squibb Co's stock?

In the past 10 years, Bristol-Myers Squibb Co has provided 0.016 (multiply by 100 for percentage) rate of return.